Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Multiple sclerosis in 2015

Managing the complexity of multiple sclerosis

The application of imaging biomarkers has provided new insights into the mechanisms of damage in multiple sclerosis (MS) and the risk of MS development and progression. The goal of eliminating all disease activity requires a timely escalation of treatment. This increasing complexity is compounded by the need to treat comorbidities.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Towards successful management of the complexity of multiple sclerosis (MS).

References

  1. Freeman, L. et al. The neuronal component of gray matter damage in multiple sclerosis: a [11C]flumazenil positron emission tomography study. Ann. Neurol. 78, 554–567 (2015).

    Article  CAS  Google Scholar 

  2. Louapre, C. et al. Beyond focal cortical lesions in MS: an in vivo quantitative and spatial imaging study at 7T. Neurology 85, 1702–1709 (2015).

    Article  Google Scholar 

  3. Salvetti, M. et al. Progressive MS: from pathophysiology to drug discovery. Mult. Scler. 21, 1376–1384 (2015).

    Article  CAS  Google Scholar 

  4. Tintore, M. et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138, 1863–1874 (2015).

    Article  Google Scholar 

  5. De Stefano, N. et al. Long-term assessment of no evidence of disease activity in relapsing–remitting MS. Neurology 85, 1722–1723 (2015).

    Article  Google Scholar 

  6. Kalincik, T. et al. Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis. Ann. Neurol. 77, 425–435 (2015).

    Article  CAS  Google Scholar 

  7. Clanet, M. C. et al. Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult. Scler. 20, 1306–1311 (2014).

    Article  Google Scholar 

  8. Marrie, R. A. et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology 85, 240–247 (2015).

    Article  Google Scholar 

  9. Marrie, R. A. et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 72, 117–124 (2009).

    Article  CAS  Google Scholar 

  10. Marrie, R. A. et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult. Scler. 21, 263–281 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

The NMR Unit and its staff are supported by the UK Multiple Sclerosis Society, National Institute for Health Research University College London Hospitals–University College London Biomedical Research Centre, the Engineering and Physical Sciences Research Council, and University College London internal funding schemes.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alan Thompson.

Ethics declarations

Competing interests

A.T. has received honoraria and support for travel for consultancy from Biogen Idec, Eisai, Genzyme, Novartis and Medday, and for speaking from EXCEMED, Novartis, Remedica and Teva. He receives an honorarium from Sage Publications as Editor-in-Chief of Multiple Sclerosis Journal. O.C. serves as a consultant for Biogen, GE Healthcare and Novartis, and payments are made to the institution; she receives an honorarium as Associate Editor of Neurology.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ciccarelli, O., Thompson, A. Managing the complexity of multiple sclerosis. Nat Rev Neurol 12, 70–72 (2016). https://doi.org/10.1038/nrneurol.2016.2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.2

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing